Baseline sampling [Regulatives / Guidelines]

posted by NK – India, 2019-06-26 07:25 (854 d 05:12 ago) – Posting: # 20360
Views: 2,449

Hello everyone,

I have a question with regards to FDA OGD guidance of Dihydroergotamine Nasal Spray" dated February 2019.

The guidance specified that "baseline corrected PK data of AUC and Cmax should be used for bio-equivalence calculation"

As per my understanding, Dihydroergotamine is neither endogenous nor available in the diet, then why baseline value is required?

If it is required, what should be baseline sampling time points (-1h or -30 min or -15 min ...)?

Thanks in advance.

Regards
NK


Edit: URL corrected. [Helmut]

Complete thread:

Activity
 Admin contact
21,758 posts in 4,550 threads, 1,545 registered users;
online 8 (1 registered, 7 guests [including 5 identified bots]).
Forum time: Wednesday 12:37 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5